IL28B polymorphism is associated with both side effects and clearance of hepatitis C during interferon-alpha therapy

Journal of Interferon and Cytokine Research

Volumn 31, Issue 3, 2011, Pages 331-336

  Lotrich, Francis E ^a   Loftis, Jennifer M ^b   Ferrell, Robert E ^c   Rabinovitz, Mordechai ^c   Hauser, Peter ^d  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d VISN 22 Network Office   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ADULT; ALLELE; APPETITE; APPETITE DISORDER; ARTICLE; BECK DEPRESSION INVENTORY; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DNA POLYMORPHISM; ENERGY; FATIGUE; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOME; GENOME ANALYSIS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; INTERVIEW; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SLEEP DISORDER; STRUCTURED INTERVIEW; VIRAL CLEARANCE; GENETICS; HEPACIVIRUS; MIDDLE AGED;

HEPATITIS C VIRUS;

ADULT; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 79952304368     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2010.0074     Document Type: Article

References (31)

1. Beck A, Steer R, Garbin M. 1988. Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clin Psychol Rev 8:77-100. (Pubitemid 18045797)
2. Bull SJ, Huezo-Diaz P, Binder EB, Cubells JF, Ranjith G, Maddock C, Miyazaki C, Alexander N, Hotopf M, Cleare AJ, Norris S, Cassidy E, Aitchison KJ, Miller AH, Pariante CM. 2008. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-a and ribavirin treatment. Mol Psychiatry 14:1095-1104.
3. Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB, Miller AH. 2002. Neurobehavioral effects of interferon-a in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 26:643-652. (Pubitemid 34260983)
4. Chen X, Levine L, Kwok PY. 1999. Fluorescence polarization in homogeneous nucleic acid analysis. Genome Res 9:492-498. (Pubitemid 29267681)
5. Costiniuk CT, Mills E, Cooper CL. 2008. Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus. Can J Gastroenterol 22:376-380. (Pubitemid 351772331)
6. First MB, Spitzer RL, Williams JBW, and others. 1995. Structured Clinical Interview for DSM-IV (SCID-1) (Users Guide and Interview) Research Version, American Psychiatric Press, Washington, D.C.
7. Fried MW. 2002. Side effects of therapy of hepatitis C and their management. Hepatology 36:S237-S244. (Pubitemid 35253486)
8. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399-401.
9. Janssen H, Brouwer J, van der Mast R, Schalm S. 1994. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 21:241-243. (Pubitemid 24270552)
10. Jen JF, Glue P, Ezzet F, Chung C, Gupta SK, Jacobs S, Hajian G. 2001. Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C. Clin Pharmacol Ther 69:407-421. (Pubitemid 32554546)
11. Kraus MR, Al-Taie O, Schefer A, Pfersdorff M, Lesch KP, Scheurlen M. 2007. Serotonin-1A receptor gene (HTR1A) vairation predicts interferon-induced depression chronic hepatitis C. Gastroenterology 132:1279-1286. (Pubitemid 46627592)
12. Loftis JM, Hauser P, Rifai MA. 2005. The association between viral clearance and depression in patients with hepatitis C receiving interferon-alpha and ribavirin. Brain Behav Immun 19:271-272.
13. Loftis JM, Socherman RE, Howell CD, Whitehead AJ, Hill JA, Dominitz JA, Hauser P. 2004. Association of interferon-alpha-induced depression and improved treatment response in patients with hepatitis C. Neurosci Lett 365:87-91. (Pubitemid 38881630)
14. Lotrich FE, Ferrell RE, Rabinovitz M, Pollock BG. 2009. Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biol Psychiatry 65:344-348.
15. Lotrich FE, Ferrell RE, Rabinovitz M, Pollock BG. 2010. Labile anger during interferon-alpha treatment is associated with a polymorphism in tumor necrosis factor-alpha. Clin Neuropharmacol 33(4):191-197.
16. Lotrich FE, Rabinovitz F, Gironda P, Pollock BG. 2007. Depression following pegylated interferon-alpha: characteristics and vulnerability. J Psychosom Res 63:131-135. (Pubitemid 47088561)
17. Maddock C, Landau S, Barry K, Maulayah P, Hotopf M, Cleare A, Norris S, Pariante CM. 2005. Psychopathological symptoms during interferon-alpha and ribavirin treatment: effects on virologic response. Mol Psychiatry 10:332-333.
18. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M-H. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965.
19. Prather AA, Rabinovitz M, Pollock BG, Lotrich FE. 2009. Cytokine-induced depression during IFN-a treatment: the role of IL-6 and sleep quality. Brain Behav Immun 23:1109-1116.
20. Raison CL, Broadwell SD, Borisov AS, Manatunga AK, Capuron L, Woolwine BJ, Jacobson IM, Nemeroff CB, Miller AH. 2005. Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun 19:23-27. (Pubitemid 39592806)
21. Rodriguez-Torres M, Rios-Bedoya CF, Ortiz-Lasanta G, Purcell-Arevalo D, Marxuach-Cuetara A, Jimenez-Rivera J. 2008. Weight affect relapse rates in latinos with genotype 2/3 chronic hepatitis C (CHC) treated with peg IFN alfa-2a (Pegasys) 180 mcg/week and 800mg daily of ribavirin for 24 weeks. J Med Virol 80:1576-1580.
22. Schwartz AL, Thompson JA, Masood N. 2002. Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate. Oncol Nurs Forum 29:E85-E90.
23. Shirakawa H, and others. 2008. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 48:1753-1760.
24. Sockalingam S, Abbey SE, Alosaimi F, Novak M. 2010. A review of sleep disturbance in Hepatitis C. J Clin Gastroenterol 44(1):38-45.
25. Su K-P, Huang S-Y, Peng C-Y, Lai H-C, Huang C-L, Chen Y-C, Aitchison KJ, Pariante CM. 2010. Phospholipase A2 and cycloxygenase 2 genes influence the risk of interferon-a-induced depression by regulating polyunsaturated faty acids levels. Biol Psychiatry 67:550-557.
26. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J. 2009. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat Genet 41:1100-1104.
27. Sylvestre DL, Clements B, Malibu Y. 2006. Cannabis use improves retention and virological outcomes in patients treated for hepatitis C. Eur J Gastroenterol Hepatol 18:1057-1063. (Pubitemid 44379358)
28. Tan H, and others. 2005. Global transcription profiling combination of type I and type II demonstrates that interferon enhances antiviral and immune responses at clinically relevant doses. J Interferon Cytokine Res 25:632-649.
29. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagaw M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. 2009. Genome-wide association of IL28B with response to pegylatyed interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105-1109.
30. Witthoft T, Moller B, Wiedmann KH, Mauss S, Link R, Lohmeyer J, Lafrenz M, Gelbmann CM, Huppe D, Niederau C, Alshuth U. 2007. Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial. J Viral Hepat 14:788-798.
31. Yoshida K, Alagbe O, Wang X, Woolwine B, Thornbury M, Raison CL, Miller AH. 2005. Promoter polymorphisms of the interferon-alpha receptor gene and development of Interferon-induced depressive symptoms in patients with chronic hepatitis C: preliminary findings. Neuropsychobiology 52:55-61. (Pubitemid 41160320)